26 – 29 It should be noted that in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study that, compared with placebo, fenofibrates failed to reach statistical significance in reducing the primary study outcome, ie, CHD or nonfatal myocardial infarction, but did show a statistically significant reduction in total cardiovascular events.
← all excerpts
Atherogenic dyslipidemia and diabetes mellitus: what's new in the management arena?
1
—
—